{
    "Trade/Device Name(s)": [
        "BioSieve\u2122 Marijuana Test Panel 50",
        "BioSieve\u2122 Marijuana Test Strip 50",
        "BioSieve\u2122 Dx Marijuana Test Strip 20",
        "BioSieve\u2122 Dx Marijuana Test Strip 50",
        "BioSieve\u2122 Dx Marijuana Test Panel 20",
        "BioSieve\u2122 Dx Marijuana Test Panel 50"
    ],
    "Submitter Information": "VivaChek Biotech (Hangzhou) Co., Ltd.",
    "510(k) Number": "K231978",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192301"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NFW"
    ],
    "Summary Letter Date": "June 27, 2023",
    "Summary Letter Received Date": "July 3, 2023",
    "Submission Date": "August 31, 2023",
    "Regulation Number(s)": [
        "21CFR862.3870"
    ],
    "Regulation Name(s)": [
        "Cannabinoid Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "11-nor-\u03949-THC-9-COOH",
        "Marijuana",
        "11-Hydroxy-9-Tetrahydrocannabinol",
        "11-Nor-8-Tetrahydrocannabinol-9-COOH",
        "Cannabinol",
        "8-Tetrahydrocannabinol",
        "9-Tetrahydrocannabinol",
        "Cannabidiol",
        "11-Nor-9-THC-carboxy glucuronide",
        "(-)-11-nor-9-carboxy-\u03949-THC"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Competitive binding assay",
        "Lateral flow immunochromatographic assay"
    ],
    "Methodologies": [
        "Antigen-antibody reaction",
        "Qualitative immunoassay",
        "Lateral flow chromatography"
    ],
    "Submission Type(s)": [
        "Panel",
        "Strip",
        "Test Device",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for BioSieve Marijuana lateral flow immunochromatographic urine test panels and strips for qualitative detection of marijuana (THC metabolite) in urine",
    "Indications for Use Summary": "Qualitative detection of marijuana in human urine at cutoff concentrations of 20 or 50 ng/mL; provides preliminary results, with confirmatory testing recommended; for in vitro diagnostic use only",
    "fda_folder": "Toxicology"
}